/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
ACRO Offers Unique Insights on Risk-Based Monitoring of Clinical Trials, and Calls for Adoption of RBM as a Best Practice
WASHINGTON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/clinicalresearch?src=hash” target=”_blank”gt;#clinicalresearchlt;/agt;–Following meetings with then-Commissioner Scott Gottlieb and senior
leadership from the Center
for Drug Evaluation and Research on the role of CROs and technology
companies in designing and implementing risk-based monitoring (RBM) of
clinical trials, the Association
of Clinical Research Organizations (ACRO) this week submitted
extensive comments on recent FDA Guidance.
Increasing the use of innovative RBM technologies helps make clinical
trials safer, more efficient and higher quality. ACRO’s comments offer
unique insights into the recent expansion of RBM implementation and call
for further increasing the use of these oversight technologies.
Having surveyed its member companies, ACRO is pleased to report that
adoption of RBM tools is growing rapidly. In 2016, less than 20 percent
of new trial starts employed some form of RBM oversight. In 2018, a
majority of new trial starts were using RBM. Challenges to
implementation of RBM remain, including perceptions that traditional
oversight methods are lower risk and less subject to critical scrutiny
by U.S. and E.U. regulators.
ACRO’s comments note that the FDA could help increase RBM implementation
by articulating stronger and more straightforward support for risk-based
monitoring approaches, specifically describing RBM as a “best practice.”
In its comments, ACRO was pleased to include a graphic describing The
Risk-Based Monitoring Landscape since 2016. “We look forward to
continuing to provide the FDA with unique insights from our member
companies,” said ACRO Executive Director, Doug Peddicord. “ACRO members
are innovators in the development of RBM technologies. We are pleased to
work with sponsors, research sites and the FDA to help ensure the safety
of trial participants and the quality of the data submitted for new
product approvals.”
About ACRO
The Association of Clinical Research Organizations (ACRO) represents
companies that provide a variety of specialized services that support
the development of new pharmaceuticals, biologics and medical devices.
Through its member companies, ACRO helps improve the quality, efficiency
and safety of biomedical research. ACRO member companies employ more
than 130,000 professionals worldwide and conduct or support the vast
majority of clinical trials.
Contacts
Matt Feldman
[email protected]
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE2 weeks ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis6 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis5 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan5 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey